🎧 New: AI-Generated Podcasts Turn your study notes into engaging audio conversations. Learn more

HIV & AIDS Nursing Notes PDF

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

Document Details

RazorSharpVerisimilitude

Uploaded by RazorSharpVerisimilitude

Cape Fear Community College

Erin Ludlum

Tags

HIV AIDS Nursing Pathophysiology

Summary

These notes cover HIV and AIDS, discussing transmission, pathophysiology, assessment, stages, opportunistic infections, treatment with antiretroviral therapy (ART), pre- and post-exposure prophylaxis (PrEP and PEP), and nursing considerations. The material details the different stages of HIV infection, the various opportunistic infections associated with AIDS, and treatment options.

Full Transcript

NUR 211 Unit 1 HIV & AIDS Erin Ludlum, MSN, RN History Incidence/Prevalence Estimated HIV Prevalence among Persons Aged ≥13 years, by Area of Residence 2019—United States and Puerto Rico Pathophysiology Retrovirus...

NUR 211 Unit 1 HIV & AIDS Erin Ludlum, MSN, RN History Incidence/Prevalence Estimated HIV Prevalence among Persons Aged ≥13 years, by Area of Residence 2019—United States and Puerto Rico Pathophysiology Retrovirus CD4 T helper cells Virus replication Retrovirus Hijacks CD4 T lymphocytes (Helper T cells) Leads to severe immunodeficiency Virus replication Pathophysiology Adams 6th ed pp. 553 Fusion Reverse transcriptase Integrase RNA Transcribes Integrates Cleaves the into DNA into host DNA proteins Protease Entry &Fusion Pathophysiology Ie VIRAL LOAD Transmission Who can spread? Most common routes of transmission: Sexual Parenteral Perinatal Sexual Transmission Parenteral Transmission Perinatal Transmission Assessment Three identified stages of HIV: Phase 1: Acute phase: Early flu-like symptoms Phase 2: Chronic phase: Assessment Phase 3: AIDS AIDS = HIV + Opportunistic infection/CA OR CD4 count drops below 200 Opportunistic Infections ○ Pneumocystis Pneumonia (PCP) ○ TB ○ Candidiasis ○ HSV or zoster ○ Cytomegalovirus ○ Wasting Syndrome Opportunistic Cancers ○ Next slide Opportunistic Infections Candidiasis: Herpes simplex virus (HSV ) or varicella-zoster virus (VZV) Pneumocystis jiroveci pneumonia (PCP) TB CMV Wasting syndrome Opportunistic Infections Malignancy: ○ Kaposi’s Sarcoma Most common Late stage Brownish purplish spots ○ Lymphoma Hodgkin & Non-Hodgkin’s & primary brain Lymphomas Affect lymphoid tissues, lymph nodes, lymphocytes, and lymphoid organs Systemic and local s/s Lymphomas Kaposi sarcoma (KS) Opportunistic Cancers ○ Cervical cancer Screening & Diagnostic Testing Rapid diagnostic tests Screening recommended for everyone ages 13-64 at least once ELISA Higher risk should be screened q6mo to annually Western blot testing Rapid diagnostic tests Enzyme-linked immunosorbent assay (ELISA) Western Blot Viral load Specific Markers CD4 ○ Viral Load – measures amount of actively replicating virus ○ CD4 count Nonspecific markers Nonspecific Markers ○ CBC ○ ESR ○ LFTs ○ Resistance testing Diagnostic Testing- HIV Diagnostic Testing Results What does a negative HIV test result mean? During window period: ? After window period: ? What does a positive HIV test result mean?  If community program or self test: ?  If health care setting or a lab: the lab will conduct the follow-up testing If the follow-up test is also positive, it means ?? Drug Therapy – labs before HIV testing starting STIs Kidney function tests Liver functions tests Because drugs can be toxic to kidney and liver Hepatitis A, B, and C PrEP has black box warning for those with Hep B Treatment: Drug Therapy Adams 6th ed pp. 553 Fusion Entry Inhibitors Reverse transcriptase RT Inhibitors Integrase Integrase Inhibitor Protease Protease Inhibitor Drug Therapy - ART Guided by CD4T cell count and viral load Combination drug regimen Strict adherence required Classifications: ○ Non-nucleoside reverse transcriptase inhibitors (NNRTI) ○ Nucleoside reverse transcriptase inhibitors (NRTI) ○ Protease inhibitors (PI) ○ Entry inhibitors ○ Integrase inhibitors Boosters: ○ Cobicistat ○ Ritonavir Drug Therapy - ART Classifications: ○ Entry inhibitors Rocks and water prevents entry ○ Maraviroc and Enfuvirtide Adv effects: Enfuvirtide is subq- pain at injection site Non-nucleoside reverse transcriptase inhibitors (NNRTI) Nucleoside reverse transcriptase inhibitors (NRTI) Adv effects: Hepatotoxicity, rash, CNS effects (dizzy, sleep d/o, fatigue) ○ Nucleoside reverse transcriptase inhibitors (NRTI) Zidovudine, Tenofovir, emtricitabine Adv effects: inhibit mitochondrial function, blood d/o, lipodystrophy ○ Integrase inhibitors *newer class Bictegravir, Dolutegravir, Elvitegravir, Raltegravir, etc Adv effects: weight gain and increased Creatine Kinase (CK) ○ Protease inhibitors (PI) Never (-navir) tease a pro-tease! Atazanavir, Darunavir, Fosamprenavir, Indinavir, etc Adv effects, GI complications (n/v), hyperglycemia and high cholesterol Drug Therapy - PrEP PrEp is pre-exposure prophylaxis Drug Therapy - PEP PEP is post-exposure prophylactic meds Drug Therapy - Pregnancy Begin ASAP (or continue taking) Pharmacotherapy of pregnant  Initiation of ART woman similar to nonpregnant  Preferred ART Regimens woman  Monitoring PrEP and PEP  Delivery Considerations  Postpartum Care Zidovudine to prevent spread to  Breastfeeding newborn  Counseling and Support Breastfeeding Treatment: Drug Therapy Goals & Evaluation ○ Lab tests to guide pharmacotherapy: Absolute CD4 T- cell count Viral load Drug Therapy – Adjunct Agents used in combination with antiretroviral therapy ○ Interferons ○ Other agents to prevent/treat OIs ○ Vaccines ○ Antibiotics ○ Symptom management Nursing BIGGEST ROLE: Education Prevention: ABC Medication Adherence Management/monitoring Avoid infections Nutrition Maintain skin Integrity Assessments: Psychosocial support/Advocacy Standard Precautions Exposure?? Avoid bias Maintain confidentiality Thanks !

Use Quizgecko on...
Browser
Browser